Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature (Q26801348)

2

0 references

Bin Xie

3

0 references

Zita Shiue

4

0 references

Behzad Najafian

5

0 references

Julie R Gralow

Creative Commons Attribution

6

0 references

language of work or name

English

0 references

publication date

22 July 2015

6 references

13 March 2019

3 April 2019

17 June 2019

12 November 2019

29 May 2020

16 July 2021

6 references

13 March 2019

3 April 2019

17 June 2019

12 November 2019

29 May 2020

16 July 2021

15

0 references

page(s)

535

0 references

issue

1

0 references

copyright license

5 references

13 March 2019

3 April 2019

17 June 2019

12 November 2019

16 July 2021

0 references

on focus list of Wikimedia project

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12885-015-1536-y

0 references

cites work

American society of clinical oncology clinical practice guideline update: recommendations on the role of bone-modifying agents in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Bisphosphonate nephrotoxicity

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Preclinical perspectives on bisphosphonate renal safety

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Breast-cancer adjuvant therapy with zoledronic acid

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1536-Y

Renal Safety and Pharmacokinetics of Ibandronate in Multiple Myeloma Patients With or Without Impaired Renal Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1536-Y

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1536-Y

Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1536-Y

Nephrotic syndrome after treatment with pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS12885-015-1536-Y

Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4510889

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study

28 November 2018

1 reference

12 December 2020

Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience

1 reference

12 December 2020

Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease

1 reference

12 December 2020

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial

1 reference

12 December 2020

Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient

1 reference

12 December 2020

Relapse of nephrotic syndrome triggered by biphosphonates

1 reference

12 December 2020

10.1186/S12885-015-1536-Y

Identifiers

DOI

0 references

Dimensions Publication ID

1001612486

0 references

Fatcat ID

release_ol5x7dg5cvhb7o5r5mlmv5whoi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ol5x7dg5cvhb7o5r5mlmv5whoi

24 November 2022